MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer.
BACKGROUND
It is known that the vast majority of prostate cancers are multifocal. However radical radiotherapy historically treats the whole gland rather than individual cancer foci.Magnetic resonance spectroscopy (MRS) can be used to non-invasively locate individual cancerous tumours in prostate. Thus an intentionally non-uniform dose distribution treating the dominant intraprostatic lesion to different dose levels than the remaining prostate can be delivered ensuring the maximum achievable tumour control probability.The aim of this study is to evaluate, using radiobiological means, the feasibility of a MRS-guided high dose rate (HDR) brachytherapy boost to the dominant lesion.


METHODS
Computed tomography and MR/MRS were performed for treatment planning of a high risk localised prostate cancer. Both were done without endorectal coil, which distorts shape of prostate during the exams.Three treatment plans were compared:- external beam radiation therapy (EBRT) only- combination of EBRT and HDR brachytherapy- combination of EBRT and HDR brachytherapy with a synchronous integrated boost to the dominant lesionThe criteria of plan comparison were: the minimum, maximum and average doses to the targets and organs at risk; dose volume histograms; biologically effective doses for organs at risk and tumour control probability for the target volumes consisting of the dominant lesion as detected by MR/MRS and the remaining prostate volume.


RESULTS
Inclusion of MRS information on the location of dominant lesion allows a safe increase of the dose to the dominant lesion while dose to the remaining target can be even substantially decreased keeping the same, high tumour control probability. At the same time an improved urethra sparing was achieved comparing to the treatment plan using a combination of EBRT and uniform HDR brachytherapy.


CONCLUSIONS
MRS-guided HDR brachytherapy boost to dominant lesion has the potential to spare the normal tissue, especially urethra, while keeping the tumour control probability high.
Kazi
Aleksandra
A
Department of Medical Physics, Townsville Teaching Hospital, Townsville, Queensland, Australia. aleksandra.kazi@health.qld.gov.au
Godwin
Guy
G
Simpson
John
J
Sasso
Giuseppe
G
D001918:Brachytherapy; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011880:Radiotherapy Planning, Computer-Assisted; D012007:Rectum / Q000528:radiation effects; D012062:Relative Biological Effectiveness; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014521:Urethra / Q000528:radiation effects
Radiology. 1996 Mar;198(3):795-805
8628874
Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1981-97
6759484
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1047-55
15519774
Australas Radiol. 2004 Dec;48(4):493-501
15601330
Radiology. 1999 Nov;213(2):481-8
10551230
Radiology. 1998 Mar;206(3):785-90
9494502
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):291-303
16618584
Acta Oncol. 2005;44(3):265-76
16076699
Br J Radiol. 2002 Feb;75(890):151-61
11893639
Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):244-54
11516874
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1085-96
10863082
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):912-4
14575821
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38
11872289
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1196-207
15234056
J Urol. 2007 Aug;178(2):529-34; discussion 534
17570425
Int J Radiat Oncol Biol Phys. 2004 Jul 1;59(3):665-73
15183469
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33
16242258
Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):921-9
10386651
Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):194-203
12504054
J Magn Reson Imaging. 2002 Dec;16(6):697-706
12451583
Urology. 2008 Dec;72(6 Suppl):S12-24
19095124
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1021-31
11429230
Radiology. 2005 Mar;234(3):804-14
15734935
Urol Clin North Am. 2002 Feb;29(1):205-12, xi
12109346